Protéine humaine recombinante LAIR1 (aa 1-165, étiquette His) fournie par Elabscience avec les spécifications techniques du collaborateur.
Know who made it. See the evidence. Buy through one marketplace.
Recombinant Human LAIR1 Protein (aa 1-165, His Tag) is a research-use recombinant protein from Elabscience preparation representing LAIR1 supplied as Lyophilized. Review the expression, purity, formulation and storage specifications below before selecting it for an assay or functional workflow.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Species | Bioactivité | Liaison | Basé sur les cellules | In Vivo | Capture ELISA |
|---|---|---|---|---|---|
| Human |
This product is manufactured by Elabscience and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
LAIR1 identifies leukocyte associated immunoglobulin like receptor 1 in Homo sapiens (Human). This target record connects NCBI Gene 3903, UniProtKB Q6GTX8 and related ABMIUM catalogue products.
